Elutia profit margin ELUT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 6.8%
Elutia's net margin works out at 427% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 53.7% |
| FY2024 | n/a | n/a | 44.1% |
| FY2023 | n/a | n/a | 44.7% |
| FY2022 | −77.1% | −78.8% | 40.1% |
| FY2021 | −52.4% | −48.6% | 40.1% |
| FY2020 | −51.1% | −31.9% | 48.2% |
| FY2019 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year |
|---|---|---|---|
| Q2 FY26 | n/a | n/a | |
| Q1 FY26 | n/a | n/a | |
| Q4 FY25 | n/a | n/a | |
| Q3 FY25 | n/a | n/a | |
| Q2 FY25 | n/a | n/a | |
| Q1 FY25 | n/a | n/a | |
| Q4 FY24 | n/a | n/a | |
| Q3 FY24 | n/a | n/a | |
| Q2 FY24 | n/a | n/a | |
| Q1 FY24 | n/a | n/a | |
| Q4 FY23 | n/a | n/a | |
| Q3 FY23 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Elutia's size, closest first, today.
| Company | Profit margin |
|---|---|
| ELUTElutia | n/m |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Elutia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.